• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

作者信息

Chong Elise A, Melenhorst J Joseph, Lacey Simon F, Ambrose David E, Gonzalez Vanessa, Levine Bruce L, June Carl H, Schuster Stephen J

机构信息

Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; and.

Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

出版信息

Blood. 2017 Feb 23;129(8):1039-1041. doi: 10.1182/blood-2016-09-738245. Epub 2016 Dec 28.

DOI:10.1182/blood-2016-09-738245
PMID:28031179
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5391777/
Abstract
摘要

相似文献

1
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.程序性死亡蛋白1（PD-1）阻断调节嵌合抗原受体（CAR）修饰的T细胞：为CAR补充能量。
Blood. 2017 Feb 23;129(8):1039-1041. doi: 10.1182/blood-2016-09-738245. Epub 2016 Dec 28.
2
Long-term treatment response to PD-1 blockade therapy in a patient with DLBCL relapsed after anti-CD19 chimeric antigen receptor T cell treatment.一名弥漫性大B细胞淋巴瘤患者在接受抗CD19嵌合抗原受体T细胞治疗后复发，其对PD-1阻断疗法的长期治疗反应
Ann Hematol. 2021 Jan;100(1):289-291. doi: 10.1007/s00277-020-03993-9. Epub 2020 Apr 25.
3
Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.理解弥漫性大 B 细胞淋巴瘤中 PD-1/PD-L1 通路相关的免疫逃逸和治疗靶点。
Int J Mol Sci. 2019 Mar 15;20(6):1326. doi: 10.3390/ijms20061326.
4
Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.嵌合抗原受体 T 细胞淋巴瘤免疫治疗：下一个问题。
Curr Opin Oncol. 2020 Sep;32(5):434-441. doi: 10.1097/CCO.0000000000000671.
5
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.免疫肿瘤学方法：嵌合抗原受体T细胞（CAR-T细胞）与免疫检查点抑制剂
Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):471-478. doi: 10.1016/j.clml.2017.06.014. Epub 2017 Jun 17.
6
Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies.嵌合抗原受体 T 细胞疗法、PD-1 阻断及其联合治疗血液系统恶性肿瘤。
Clin Immunol. 2020 May;214:108382. doi: 10.1016/j.clim.2020.108382. Epub 2020 Mar 10.
7
Resistance to PD-1 blockade in melanoma.黑色素瘤对PD-1阻断的耐药性。
Lancet Oncol. 2016 Sep;17(9):e376. doi: 10.1016/S1470-2045(16)30372-2. Epub 2016 Jul 22.
8
Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre.使用程序性死亡受体 1（PDCD1）抑制剂治疗 Richter 综合征：单学术中心经验
Br J Haematol. 2019 Apr;185(2):363-366. doi: 10.1111/bjh.15508. Epub 2018 Jul 20.
9
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.PD-1/PD-L1 通路及其阻断在经典霍奇金淋巴瘤和非霍奇金大细胞淋巴瘤患者中的作用。
Curr Hematol Malig Rep. 2020 Aug;15(4):372-381. doi: 10.1007/s11899-020-00589-y.
10
Pembrolizumab for classical Hodgkin's lymphoma.帕博利珠单抗用于经典型霍奇金淋巴瘤。
Lancet Oncol. 2016 Aug;17(8):e324. doi: 10.1016/S1470-2045(16)30301-1. Epub 2016 Jul 7.

引用本文的文献

1
Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions.实体瘤中CAR-T细胞疗法的进展：现状与未来方向
Cancers (Basel). 2025 Sep 3;17(17):2898. doi: 10.3390/cancers17172898.
2
Challenges in the preclinical design and assessment of CAR-T cells.嵌合抗原受体T细胞（CAR-T细胞）临床前设计与评估中的挑战。
Front Immunol. 2025 Aug 8;16:1564998. doi: 10.3389/fimmu.2025.1564998. eCollection 2025.
3
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model.在BCMA嵌合抗原受体T细胞（BCMA-CART）细胞疗法背景下，阻断TIGIT在多发性骨髓瘤小鼠模型中并不会增强疗效。
Oncoimmunology. 2025 Dec;14(1):2529632. doi: 10.1080/2162402X.2025.2529632. Epub 2025 Jul 12.
4
Functionalized chitosan as nano-delivery platform for CRISPR-Cas9 in cancer treatment.功能化壳聚糖作为CRISPR-Cas9在癌症治疗中的纳米递送平台。
Asian J Pharm Sci. 2025 Jun;20(3):101041. doi: 10.1016/j.ajps.2025.101041. Epub 2025 Feb 26.
5
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.下一代免疫疗法设计与工具的见解：分子机制与治疗前景。
J Hematol Oncol. 2025 Jun 7;18(1):62. doi: 10.1186/s13045-025-01701-6.
6
An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy.抗CD19嵌合抗原受体T细胞疗法后复发/难治性弥漫性大B细胞淋巴瘤患者中，探索程序性死亡受体1抑制剂/程序性死亡受体1抑制剂联合化疗作为挽救治疗的起始时间及患者选择
Cell Transplant. 2025 Jan-Dec;34:9636897251338713. doi: 10.1177/09636897251338713. Epub 2025 Jun 5.
7
Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines.血液癌症的新一代免疫治疗方法：探索嵌合抗原受体T细胞（CAR-T）和癌症疫苗的疗效。
Exp Hematol Oncol. 2025 May 17;14(1):75. doi: 10.1186/s40164-025-00662-3.
8
Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy.克服CAR-T疗法后因抗原逃逸导致肿瘤复发的策略。
Mol Cancer. 2025 Apr 28;24(1):126. doi: 10.1186/s12943-025-02334-6.
9
Strategies for Altering Delivery Technologies to Optimize CAR Therapy.改变递送技术以优化嵌合抗原受体（CAR）疗法的策略。
Int J Mol Sci. 2025 Mar 30;26(7):3206. doi: 10.3390/ijms26073206.
10
Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell Lymphoma.原发性纵隔大B细胞淋巴瘤靶向治疗的当前问题与未来展望
J Clin Med. 2025 Feb 11;14(4):1191. doi: 10.3390/jcm14041191.

本文引用的文献

1
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.嵌合抗原受体T细胞在复发难治性慢性淋巴细胞白血病中持续存在并诱导持续缓解。
Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.
2
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.纳武利尤单抗治疗晚期黑色素瘤患者的生存、持久肿瘤缓解和长期安全性。
J Clin Oncol. 2014 Apr 1;32(10):1020-30. doi: 10.1200/JCO.2013.53.0105. Epub 2014 Mar 3.
3
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.抗 PD-1 抗体治疗可显著增强基因修饰 T 细胞对已建立肿瘤的清除作用。
Clin Cancer Res. 2013 Oct 15;19(20):5636-46. doi: 10.1158/1078-0432.CCR-13-0458. Epub 2013 Jul 19.
4
Nivolumab plus ipilimumab in advanced melanoma.纳武利尤单抗联合伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
5
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.拉罗替尼（anti-PD-1）治疗黑色素瘤的安全性和肿瘤应答。
N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.
6
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.抗 PD-L1 抗体在晚期癌症患者中的安全性和活性。
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
7
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
8
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.含有CD137信号转导结构域的嵌合受体介导T细胞在体内的存活率提高及抗白血病疗效增强。
Mol Ther. 2009 Aug;17(8):1453-64. doi: 10.1038/mt.2009.83. Epub 2009 Apr 21.